ClinicalTrials.gg
CompletedNCT05806359Updated May 23, 2024

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

A Phase 1 interventional study of Danicamtiv and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy
  • Danicamtiv
  • Japanese
  • Caucasian
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 30 kilograms/meter squared inclusive, at the screening visit.
  • Japanese participants must be of Japanese descent (both biological parents are ethnically Japanese).
  • Caucasian participants must be of European or Latin American Caucasian descent.
  • A female participant is eligible to participate if she is a woman of nonchildbearing potential as defined in the protocol.
  • Males who are sexually active with woman of must agree to follow protocol-defined instructions for method(s) of .

Exclusion criteria

Exclusion Criteria:

  • Any acute or chronic medical illness.
  • Active infection, including with coronavirus disease-19, diagnosed clinically by the investigator.
  • History of any other disorder, condition, or disease that, in the opinion of the investigator or sponsor clinical trial physician, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.

Note: Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Japanese Cohort - Dose 1

    Drug: Danicamtiv · Drug: Placebo

  • Experimental
    Japanese Cohort - Dose 2

    Drug: Danicamtiv · Drug: Placebo

  • Experimental
    Japanese Cohort - Dose 3

    Drug: Danicamtiv · Drug: Placebo

  • Experimental
    Caucasian Cohort - Dose 3

    Drug: Danicamtiv · Drug: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986434, MYK-491

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    Time frame: Day 1 up to Day 28

  2. Number of Participants with Vital Sign Abnormalities

    Time frame: Day 1 up to Day 7

  3. Number of Participants with Electrocardiogram (ECG) Abnormalities

    Time frame: Day 1 up to Day 7

  4. Number of Participants with Physical Examination Abnormalities

    Time frame: Day 1 up to Day 7

  5. Number of Participants with Clinical Laboratory Abnormalities

    Time frame: Day 1 up to Day 7

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Predose and at multiple timepoints (Day 1 up to Day 6) after dosing

  2. Time of Maximum Observed Plasma Concentration (Tmax)

    Time frame: Predose and at multiple timepoints (Day 1 up to Day 6) after dosing

  3. Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(0-inf)]

    Time frame: Predose and at multiple timepoints (Day 1 up to Day 6) after dosing

07

Study locations

1 site
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Aug 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 10, 2023
StartActual
Mar 31, 2023
Primary completionActual
Aug 14, 2023
CompletionActual
Aug 14, 2023
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05806359
Responsible party
Sponsor
First posted
Apr 10, 2023
Start date
Mar 31, 2023
Primary completion
Aug 14, 2023
Completion
Aug 14, 2023
Last update
May 23, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danicamtiv

Start the discussion